1-3 of 3
Ranjan Tiwari
Close
Sort by
Journal Articles

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

Michael R. Verneris, Qiufei Ma, Jie Zhang, Amy Keating, Ranjan Tiwari, Junlong Li, Hongbo Yang, Abhijit Agarwal, Lida Pacaud
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5387–5395.
https://doi.org/10.1182/bloodadvances.2020004045
Published: 2021
Journal Articles

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Richard T. Maziarz, Edmund K. Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J. Schuster, Michael R. Bishop, Jason R. Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R. Foley, Peter Borchmann, Gilles A. Salles, Jie Zhang, Ranjan Tiwari, Lida B. Pacaud, Qiufei Ma, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (4): 629–637.
https://doi.org/10.1182/bloodadvances.2019001026
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019